Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:MLSS NASDAQ:NEPH NYSE:NSPR NASDAQ:QNRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMLSSMilestone Scientific$0.37$0.35$0.22▼$0.88$32.84M1.041.24 million shs414,196 shsNEPHNephros$3.15$3.27$2.66▼$6.42$34.20M1.5114,746 shs11,323 shsNSPRInspireMD$0.71$1.06$0.69▼$2.93$33.26M0.74181,537 shs104,991 shsQNRXQuoin Pharmaceuticals$4.65$5.40$4.10▼$41.80$9.34M1.5631,241 shs6,555 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMLSSMilestone Scientific+9.24%+3.43%+7.00%+50.69%-57.78%NEPHNephros-1.56%-5.41%-13.22%+8.25%-12.01%NSPRInspireMD-3.79%-2.65%-29.00%-60.77%-70.66%QNRXQuoin Pharmaceuticals+0.65%-1.06%-10.06%-42.27%-44.64%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMLSSMilestone Scientific$0.37$0.35$0.22▼$0.88$32.84M1.041.24 million shs414,196 shsNEPHNephros$3.15$3.27$2.66▼$6.42$34.20M1.5114,746 shs11,323 shsNSPRInspireMD$0.71$1.06$0.69▼$2.93$33.26M0.74181,537 shs104,991 shsQNRXQuoin Pharmaceuticals$4.65$5.40$4.10▼$41.80$9.34M1.5631,241 shs6,555 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMLSSMilestone Scientific+9.24%+3.43%+7.00%+50.69%-57.78%NEPHNephros-1.56%-5.41%-13.22%+8.25%-12.01%NSPRInspireMD-3.79%-2.65%-29.00%-60.77%-70.66%QNRXQuoin Pharmaceuticals+0.65%-1.06%-10.06%-42.27%-44.64%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMLSSMilestone Scientific 3.00Buy$1.00169.32% UpsideNEPHNephros 2.50Moderate Buy$6.0090.48% UpsideNSPRInspireMD 3.00Buy$4.50533.80% UpsideQNRXQuoin Pharmaceuticals 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest QNRX, NEPH, NSPR, and MLSS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/15/2026QNRXQuoin Pharmaceuticals ThinkEquitySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy6/4/2026NEPHNephros Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Hold (C-)5/21/2026NEPHNephros Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C-) ➝ Hold (C)5/7/2026NEPHNephros Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Hold (C-)5/5/2026NSPRInspireMD Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$4.00 ➝ $3.005/4/2026NSPRInspireMD Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$4.004/22/2026QNRXQuoin Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026NEPHNephros Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)(Data available from 6/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMLSSMilestone Scientific$8.90M3.69N/AN/A$0.11 per share3.38NEPHNephros$18.79M1.82$0.13 per share25.11$0.96 per share3.28NSPRInspireMD$10.85M3.07N/AN/A$1.83 per share0.39QNRXQuoin PharmaceuticalsN/AN/AN/AN/A$15.64 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMLSSMilestone Scientific-$6.93M-$0.05N/AN/AN/A-52.01%-60.26%-40.23%N/ANEPHNephros$1.19M$0.0745.01N/AN/A4.06%7.66%5.86%8/6/2026 (Estimated)NSPRInspireMD-$19.92M-$0.73N/AN/AN/A-413.96%-69.42%-57.68%N/AQNRXQuoin Pharmaceuticals-$15.81M-$29.56N/AN/AN/AN/A-489.85%-221.29%8/6/2026 (Estimated)Latest QNRX, NEPH, NSPR, and MLSS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026NEPHNephros$0.01$0.01N/A$0.01$5.02 million$5.21 million5/7/2026Q1 2026QNRXQuoin Pharmaceuticals-$2.17-$1.77+$0.40-$1.77N/AN/A3/27/2026Q4 2025QNRXQuoin Pharmaceuticals-$6.42-$14.80-$8.38-$1.74N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthMLSSMilestone ScientificN/AN/AN/AN/AN/ANEPHNephrosN/AN/AN/AN/AN/ANSPRInspireMDN/AN/AN/AN/AN/AQNRXQuoin PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMLSSMilestone ScientificN/A2.851.86NEPHNephrosN/A4.553.12NSPRInspireMDN/A6.396.05QNRXQuoin PharmaceuticalsN/A2.872.87Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMLSSMilestone Scientific5.79%NEPHNephros41.10%NSPRInspireMD44.78%QNRXQuoin Pharmaceuticals8.63%Insider OwnershipCompanyInsider OwnershipMLSSMilestone Scientific12.51%NEPHNephros6.70%NSPRInspireMD34.06%QNRXQuoin Pharmaceuticals13.46%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMLSSMilestone Scientific3088.45 million58.61 millionOptionableNEPHNephros3010.86 million10.13 millionNot OptionableNSPRInspireMD5046.84 million18.33 millionOptionableQNRXQuoin Pharmaceuticals42.01 million1.74 millionNot OptionableQNRX, NEPH, NSPR, and MLSS HeadlinesRecent News About These CompaniesQuoin Pharmaceuticals Completes Establishment of Japanese Subsidiary to Advance Commercial Readiness for QRX003June 18 at 8:30 AM | globenewswire.comQuoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use ProgramJune 16 at 8:30 AM | globenewswire.comQuoin Pharmaceuticals Announces Japan's MHLW Grants Orphan Drug Designation for QRX003 in Netherton SyndromeJune 4, 2026 | globenewswire.comQuoin Pharmaceuticals Submits IND Application for QRX003 in Peeling Skin SyndromeJune 2, 2026 | globenewswire.comQuoin Pharmaceuticals. Ltd Sponsored ADRMay 19, 2026 | edition.cnn.comQuoin Pharmaceuticals (QNRX) Receives a Buy from Maxim GroupMay 9, 2026 | theglobeandmail.comQuoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial ResultsMay 7, 2026 | globenewswire.comQuoin Pharmaceuticals to Announce Corporate Update and First Quarter 2026 Financial Results on Thursday, May 7, 2026April 30, 2026 | globenewswire.comCORRECTION -- Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development ProgramsApril 28, 2026 | globenewswire.comQuoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development ProgramsApril 28, 2026 | globenewswire.comQNRX: Preparing to Commercialize Lead Asset Through Global Sales InfrastructureApril 15, 2026 | msn.comMaxim Group Sticks to Its Buy Rating for Quoin Pharmaceuticals (QNRX)April 11, 2026 | theglobeandmail.comQuoin Pharmaceuticals - Depositary Receipt (QNRX) price target increased by 12.66% to 30.26April 10, 2026 | msn.comQuoin Pharmaceuticals - Depositary Receipt (QNRX) price target decreased by 36.80% to 26.86March 27, 2026 | msn.comQuoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial ResultsMarch 26, 2026 | markets.businessinsider.comQNRX stock surges 20% pre-market – what did the FDA say about Netherton syndrome lead drug?March 26, 2026 | msn.comQuoin advances QRX003 development after positive FDA meeting on Netherton syndromeMarch 26, 2026 | msn.comQuoin Pharmaceuticals Provides Clinical and Regulatory Update from Constructive Type C Meeting with U.S. FDA for QRX003 in Netherton SyndromeMarch 25, 2026 | globenewswire.comQuoin Pharmaceuticals to Announce Corporate Update and Fourth Quarter and Full-Year 2025 ...March 19, 2026 | caledonianrecord.comCQuoin Pharmaceuticals to Announce Corporate Update and Fourth Quarter and Full-Year 2025 Financial Results on Thursday, March 26, 2026March 19, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeQNRX, NEPH, NSPR, and MLSS Company DescriptionsMilestone Scientific NYSE:MLSS$0.37 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$0.36 -0.01 (-3.31%) As of 06/18/2026 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Milestone Scientific Inc., a biomedical technology research and development company, patents, designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical, dental, and cosmetic use in the United States, China, and internationally. The company operates through Dental and Medical segments. Its products include CompuDent and STA Single Tooth Anesthesia System that are used for all dental procedures that require local anesthetic. In addition, the company offers CompuFlo, a computer-controlled drug delivery system for the painless delivery of drugs, anesthetics, and other medicaments, as well as for the aspiration of bodily fluids or previously injected substances, and disposable injection handpiece for the tactile control during the injection. Further, it provides CompuFlo Epidural, a computer-controlled anesthesia system for use in various medical applications. Additionally, the company offers company offers CompuMed for use in various medical procedures performed in plastic, hair restoration, and colorectal surgery, as well as podiatry, dermatology, orthopedics, and various other disciplines. Milestone Scientific Inc. was incorporated in 1989 and is headquartered in Roseland, New Jersey.Nephros NASDAQ:NEPH$3.15 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$3.18 +0.04 (+1.11%) As of 06/18/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, cysts, particulates, and scale build-up in downstream equipment. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.InspireMD NYSE:NSPR$0.71 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$0.72 +0.01 (+1.13%) As of 06/18/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.Quoin Pharmaceuticals NASDAQ:QNRX$4.65 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$4.72 +0.07 (+1.61%) As of 06/18/2026 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself? Why Kroger’s Pullback Could Be a Gift for Patient Investors Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Why Palantir’s Google Cloud Deal Could Change the Debate VMware: Broadcom's Second Biggest Business Set to Accelerate American Eagle’s Q1 Beat Leaves Investors With a Bigger Question Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
